January 9, 2026 — Leads & Copy — Revvity, Inc. and Eli Lilly and Company (Lilly) are collaborating to expand access to Lilly’s predictive models through the Revvity Signals platform.
The collaboration will make Lilly TuneLab available through the Revvity Signals platform and builds on Revvity’s recently introduced Signals Xynthetica offering, creating a framework to accelerate AI-enabled drug discovery.
Lilly TuneLab was established to make AI/ML models, trained on Lilly research data, available to the biotech community in exchange for data contributions. The Signals Xynthetica platform operationalizes the delivery of the Lilly TuneLab models directly within the Signals platform, where experimental data is already captured, curated, and analyzed.
Kevin Willoe, president of Revvity Signals Software, said federated learning requires the right platform to succeed. He added that by providing access to Lilly’s predictive models through the Signals Xynthetica platform, Revvity is creating a way for organizations to contribute to, and benefit from, collective intelligence.
Participating organizations will be able to apply Lilly’s predictive models to their own discovery programs while keeping proprietary data private and secure through Revvity’s Models-as‑a‑Service framework and its Signals Xynthetica offering. This approach amplifies the value of contributions from small and midsized‑biotechs, whose data can enhance predictive performance.
The Signals platform provides infrastructure to enable organizations to access the Lilly TuneLab models, including scientific data management, analytics, and collaboration. Revvity’s Signals One offering supports wet-lab data capture and orchestration, and its Signals Synergy module enables secure data exchange with CROs, academic collaborators, and partners.
Lilly and Revvity will jointly fund access for selected participants, including access to Signals One and Signals Xynthetica software offerings and modeling credits. This co-funded model lowers barriers to AI adoption and accelerates innovation across the biotech ecosystem.
Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Contact:
Kevin Willoe, president of Revvity Signals Software.
Source: Revvity, Inc.
